FBLG press release
Key Highlights
- ➤Initial CYWC628 safety data expected mid-December 2026
- ➤Interim CYWC628 efficacy data anticipated in February 2027
- ➤Issued patents increased 38% year to date to 170
- ➤Third-quarter operating expenses fell 19% year over year
- ➤Third-quarter net loss approximately $4.0 million; cash totaled $1.2 million
Expert Statements
Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics
“The third quarter was focused on continued execution. We continued enrollment in our Phase 1/2 diabetic foot ulcer trial, released our third batch of CYWC628 drug product and grew our issued patents by 38% this year, all while reducing operating expenses by 19%”
FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts PR Newswire
* Initial safety data from Phase 1/2 CYWC628 diabetic foot ulcer trial expected in Q4 2026; interim efficacy data expected in Q1 2027 * Issued patents increased 38% year to date to 170, with more than 325 issued and pending worldwide * Total operating expenses decreased 19% year over year HOUSTON, Nov. 16, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials with more than 325 patents issued and pending worldwide, reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
Get started
Create a free account to read the full story.
